NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Niagen Bioscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$2.50+0.01 (+0.40%)
Close on Oct 19, 2026
- Market cap
- $206.26M
- P/E (TTM)
- 13.9
- Dividend yield
- –
Share price
−$4.83 (−65.89%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Niagen Bioscience, Inc. grew revenue 11.0% to $129.08M over the twelve months to Jun 30, 2026. Operating income fell 36.4% to $10.60M, moving the operating margin from 14.3% to 8.2%.
Revenue
$129.08M
+11.0% vs. a year earlier
Operating income
$10.60M
-36.4% vs. a year earlier
EPS, diluted
$0.18
-14.3% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $206.26M
- P/E ratio
- 13.9
- Price to sales
- 1.60
- Price to book
- 2.50
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $129.08M
- Net income
- $15.99M
- EPS, diluted
- $0.18
- Book value per share
- $1.00
- Diluted shares
- 83M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$129.08M+11.0% YoY
Gross profit
$82.92M+12.1% YoY
Operating income
$10.60M-36.4% YoY
Net income
$15.99M-9.8% YoY
EPS, diluted
$0.18-14.3% YoY
Free cash flow
–
Reported periodTrailing twelve months